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In 1882, Robert Koch suggested four pos-
tulates that establish causation between
an infectious agent and a particular dis-
ease: (1) the infectious organism must be
found in abundance in all diseased, but
not in healthy, organisms, (2) the infec-
tious organism must be isolated from the
diseased host and grown in culture, (3)
the disease must be reproduced when the
cultured organism is introduced into a
healthy organism and (4) the same organ-
ism must be reisolated from the exper-
imentally diseased host (Tabrah, 2011;
Breitschwerdt et al., 2013). In Figure 1 we
suggest an adaptation to the original pos-
tulates of Koch to be used as a framework
to assess the causation between intestinal
Pseudomonas aeruginosa and intestinal dis-
ease in patients with cancer. In the follow-
ing sections we describe the prevalence of
P. aeruginosa in cancer and the immuno-
suppressive and stress-inducing condi-
tions of cancer that facilitate the growth,
dissemination and virulence of intestinal
P. aeruginosa. In addition, we describe
work showing that P. aeruginosa promotes
intestinal epithelium cancer-related phe-
notypes when introduced in tumor prone
model hosts.
CANCER AND OTHER
IMMUNOSUPPRESSIVE CONDITIONS
PROMOTE THE PREVALENCE OF
P. aeruginosa
Bacteremia is a major cause of life-
threatening complications in patients with
cancer, especially those who receive anti-
cancer chemotherapy. Cancer patients
are more vulnerable to invasive infec-
tion, due to ulcerative lesions in mucosal
surfaces and immune suppression sec-
ondary to chemotherapy (Safdar and
Armstrong, 2001). Many studies asso-
ciate bloodstream infections in cancer
patients with Gram-negative bacteria
(Oliveira et al., 2007; Bos et al., 2013;
Montassier et al., 2013).
P. aeruginosa is a Gram-negative
opportunistic bacterium that causes
various infections. Common community-
acquired infections with P. aeruginosa are
skin and soft tissue infections, ulcerative
keratitis and otitis externa, while hospital-
acquired infections include bloodstream
infections, pneumonias and urinary tract
infections (Driscoll et al., 2007). Infections
may be associated with a high rate of
morbidity and mortality in immunocom-
promised hosts, such as those suffering
from chemotherapy-induced neutrope-
nia, patients with cystic fibrosis or severe
burns and individuals who receive inten-
sive care (Driscoll et al., 2007; Kerr and
Snelling, 2009; Worth and Slavin, 2009;
Stuart et al., 2010; Rafla and Tredget,
2011).
P. aeruginosa intestinal carriage
increases from ∼3% in normal people to
∼20% in hospitalized patients (Stoodley
and Thom, 1970). In a case-control study
the intestinal colonization by P. aeruginosa
in cancer patients was 10%before and 31%
after hospitalization (Andremont et al.,
1989). Studies conducted in oncology–
hematology units, found an overall
intestinal carriage of P. aeruginosa between
11.7 and 37% (Thuong et al., 2003). In
another case-control study P. aeruginosa
intestinal colonization was identified in
17% of controls and 60% of blood can-
cer patients (Vuotto et al., 2013). These
epidemiology data suggest that intestinal
colonization by P. aeruginosa is promi-
nent among hospitalized cancer patients
(Andremont et al., 1989; Vuotto et al.,
2013).
The intestinal carriage of P. aeruginosa
is likely a consequence of the opportunistic
nature of this species. Most P. aeruginosa
infections appear secondary to a breach in
host defences. In addition to compromised
host immunity, intestinal microbiota play
a major role in intestinal defence to infec-
tion (Levison, 1973). Thus systemic expo-
sure to antibiotics, which alters intestinal
microbiota by reducing the abundance of
certain microbes creates the opportunity
for intestinal growth of P. aeruginosa and
other pathogenic bacteria (Hentges et al.,
1985).
INTESTINAL P. aeruginosa AS A
SOURCE OF SYSTEMIC AND REMOTE
INFECTIONS
The translocation of endogenous intesti-
nal P. aeruginosa extraluminally is an
important pathogenic phenomenon and
a cause of systemic infections, especially
in neutropenic patients with hematolog-
ical malignancies (Okuda et al., 2010).
During the translocation process, bacte-
ria and their products cross the intestinal
barrier by traveling between or through
the cells of the intestinal epithelium, caus-
ing infection and massive inflammation
(Alexander et al., 1990; Papoff et al., 2012).
Lung infections caused by P. aeruginosa
are frequent in patients and can occur by
direct contamination of the lungs by gas-
trointestinal flora or through hematoge-
nous spread from the intestine to the
lungs. Sepsis and mortality in immuno-
compromised patients are the results of
the presence of highly virulent strains of
P. aeruginosa within the intestinal tract
and the pathogen’s ability to adhere to the
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FIGURE 1 | An adaptation of Koch’s postulates assessing causation
between intestinal P. aeruginosa and disease in patients with cancer.
Studies using Drosophila and mammalian hosts may assess the role of P.
aeruginosa in facilitating intestinal disease, including intestinal P. aeruginosa
growth, dissemination, virulence and tumorigenesis, in predisposed hosts. In
addition, clinical studies can be designed to assess the presence of P.
aeruginosa in cancer patients and its role in intestinal disease, including
tumorigenesis for which clinical data are lacking.
intestinal epithelial barrier (Marshall et al.,
1993; Alverdy et al., 2000; Osmon et al.,
2004; Zaborina et al., 2006; Okuda et al.,
2010).
P. aeruginosa uses different virulence
factors that can damage epithelial cells,
such as enzymes (proteases and elastases),
toxins, adhesins, flagella and protein secre-
tion systems (Sundin et al., 2004). The
T3SS enables the injection of at least four
effector proteins (ExoS, ExoT, ExoU, and
ExoY) into the host cell. ExoS injected
into the host epithelial cell migrates to the
membrane where it binds to the mam-
malian factor FXYD3, expressed specifi-
cally in the colon and stomach (Okuda
et al., 2010). Thus, ExoS may assist
the penetration of P. aeruginosa through
the intestinal epithelial barrier, impair-
ing the defence function of tight junc-
tions against bacterial penetration (Okuda
et al., 2010). Moreover, gut inflammation
and apoptosis–which can be initiated by
the Pseudomonas quinolone signal (PQS)–
lead to tight junction disruption and an
increase of epithelial barrier permeability
(Alverdy et al., 2005; An, 2008). Similarly,
P. aeruginosa lectin PA-I, which is associ-
ated with adhesion to epithelial cell layer,
is produced after intestinal ischemia and
secreted into the intestinal lumen, caus-
ing tight junction interruption, epithelial
barrier dysfunction and increase of its per-
meability (Seal et al., 2011).
INTESTINAL P. aeruginosa EXHIBITS
ENHANCED VIRULENCE UPON STRESS,
SURGERY, TRAUMA, AND MAYBE
CANCER
Cohort studies show that infections are
more frequent, severe and lethal among
surgical patients (Craven et al., 1988;
Sax et al., 2011). Surgical injury can
shift the dynamics of the host-pathogen
interaction leading to phenotype trans-
formation or phase variation that devel-
ops as microbes adapt and respond
to novel environments, causing mor-
bidity and mortality (Babrowski et al.,
2013). P. aeruginosa escalates its viru-
lence and promotes systemic inflamma-
tion during various conditions of host
stress (Seal et al., 2011). In patients col-
onized by P. aeruginosa, the prolonged
surgical injury releases stress-related host
factors that can trigger the otherwise
dormant colonizers, making them inva-
sive and lethal (Babrowski et al., 2013).
Defence mechanisms such as degrada-
tive proteases and lipases, exopolysaccha-
ride capsule and outer membrane-derived
vesicles (OMVs), which serve as a secre-
tion mechanism for virulence factors,
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help the pathogen to survive in the
host environment (Macdonald and Kuehn,
2013). OMVs are induced in response to
physiological stressors and secreted dur-
ing infection serving multiple roles in
bacterial pathogenesis (Macdonald and
Kuehn, 2013). In surgically stressed hosts
interferon-gamma, endogenous opioids
and the hypoxic end-products adenosine
and inosine are released into the intesti-
nal lumen where they bind bacteria and
activate the expression of PA-I lectin and
other virulence factors of P. aeruginosa.
The PA-I lectin alters the tight junction
permeability of the intestinal epithelium to
exotoxin A, leading to lethal gut derived
sepsis (Long et al., 2008). Moreover, local
intestinal depletion of extracellular phos-
phate (hypophosphatemia), which occurs
after surgical injury, can activate virulent
pathways due to bacterial sensing of low
phosphate, shifting the phenotype of P.
aeruginosa to that of a lethal strain (Long
et al., 2008). Because interferon-gamma,
opioids and hypoxia are part of the host
response and the therapeutic regiments
administered to cancer patients (Dunn
et al., 2005; Vaupel and Mayer, 2007),
the conditions that accompany cancer may
also provide the signals for P. aeruginosa
virulence induction.
CAN P. aeruginosa SIMILARLY TO
OTHER GASTROINTESTINAL BACTERIA
FACILITATE CANCER?
Bacteria may initiate oncogenesis because
they can induce inflammation and pro-
duce cell damaging toxins that facili-
tate tumorigenesis (Collins et al., 2011;
Tjalsma et al., 2012). The characteristic
single polar flagella and type 4 pili of P.
aeruginosa function as initiators of inflam-
mation and adhesins, respectively (Gellatly
and Hancock, 2013). P. aeruginosa induces
Toll-like receptors to activate cytokines,
chemokines and COX-2 and recruit cells
of the innate and adaptive immune sys-
tem (Hussain et al., 2003; Holt et al.,
2008; de Lima et al., 2012). Epithelial
adherence is a property of various bac-
teria associated with gastrointestinal dis-
ease and cancer, such as Bacteroides frag-
ilis, Streptococcus bovis, Escherichia coli and
Helicobacter pylori (Toprak et al., 2006;
Selgrad et al., 2008; Abdulamir et al., 2011;
Arthur et al., 2012). Cell wall antigens of S.
bovis induce overexpression of COX-2 and
NF-κB in vitro, which promote cellular
proliferation and angiogenesis (Tafe and
Ruoff, 2007; Abdulamir et al., 2009).
E-cadherin, a cell adhesion molecule
serves as an antagonist of invasion and
metastasis and is found mutated in human
carcinomas (Cavallaro and Christofori,
2004; Berx and van Roy, 2009). B. frag-
ilis secreted factor BFT cleaves E-cadherin,
which is usually bound inside the plasma
membrane to β-catenin. The cleavage
releases catenin in the cytosol leading to
the transcription of the oncogene c-myc
(Hardy et al., 2000). Similarly, P. aerug-
inosa secreted factor LasI can disrupt
adherens junctions and reduce the expres-
sion and distribution of E-cadherin and
β-catenin in the cell membrane, result-
ing in changes in cell junction associations
and enhanced paracellular permeability
(Vikström et al., 2009).
Interestingly, intestinal innate immune
responses and stem cells may drive tumor
initiation, maintenance and metastasis
(Schwitalla et al., 2013). Cancer develop-
ment is assisted by apoptotic programmed
cell death in the tumor microenviron-
ment (Evan and Littlewood, 1998; Lowe
et al., 2004; Adams and Cory, 2007)
and P. aeruginosa uses many virulence
factors that induce epithelial cell apop-
tosis. Intestinal infection with P. aerug-
inosa in Drosophila activates the c-Jun
N-terminal kinase (JNK) pathway, which
causes apoptosis of enterocytes and leads
to proliferation of intestinal stem cells
(Apidianakis et al., 2009). Importantly,
genetic predisposition via an oncogenic
form of Ras1/K-Ras oncogene, can syner-
gize with inflammatory signals to induce
stem cell-originating tumors character-
ized by alterations in cell polarity and
tissue architecture. Moreover, sustained
intestinal infection with P. aeruginosa in
Drosophila induces the Imd/NF-κB path-
way, which synergizes with the oncogene
Ras1V12 to activate the JNK pathway.
This leads to invasion and dissemina-
tion of oncogenic hindgut cells to dis-
tant sites (Bangi et al., 2012; Christofi and
Apidianakis, 2013).
CONCLUSIONS
P. aeruginosa is a common colonizer
of the human intestine upon hospi-
talization, immunosuppression, antibiotic
treatment, surgery, severe trauma and
other conditions that cancer patients may
face. Not only is P. aeruginosa car-
riage increased in the aforementioned
conditions, but also bacteria become more
virulent and damaging to the intesti-
nal epithelium upon surgery, injury, and
severe stress. Moreover, human isolates of
P. aeruginosa can induce intestinal pathol-
ogy and cancer-related epithelial pheno-
types in genetically predisposed model
hosts. Thus, P. aeruginosa appears to have
the opportunity and the ability to promote
intestinal disease in predisposed hosts,
although further proof on the ability of
this bacterium to promote tumorigenesis
in mammalian models of infection is
needed. The lack of epidemiological data
linking P. aeruginosa to intestinal disease
and potentially tumorigenesis in cancer
patients may reflect the lack of clinical
studies assessing bacterial growth and vir-
ulence in relation to cancer recurrence.
Because the titter, distribution and vir-
ulence of P. aeruginosa in the intestine
may be very dynamic (Tjalsma et al.,
2012), future studies should be designed
to repeatedly assess intestinal P. aerug-
inosa abundance and virulence in can-
cer patients versus healthy individuals.
Clinical samples can be assessed for
the presence of P. aeruginosa via clas-
sical microbiology, and next-generation
sequencing may offer the chance to assess
P. aeruginosa transcriptome during infec-
tion. Importantly, definite proof of cau-
sation of P. aeruginosa in morbidity and
mortality of cancer patients can only
be achieved if targeted elimination of P.
aeruginosa from these patients improves
the outcome of their disease. In Figure 1
we illustrate a roadmap to specifically
assess the role of P. aeruginosa in intestinal
disease and tumorigenesis. It is conceiv-
able that similar principles can be used to
assess causality between intestinal disease
and many other opportunistic pathogens
harbored by the human gut.
REFERENCES
Abdulamir, A. S., Hafidh, R. R., and Abu Bakar,
F. (2011). The association of streptococcus
bovis/gallolyticus with colorectal tumors: the
nature and the underlying mechanisms of its
etiological role. J. Exp. Clin. Cancer Res. 30, 11.
doi: 10.1186/1756-9966-30-11
Abdulamir, A. S., Hafidh, R. R., Mahdi, L. K.,
Al-jeboori, T., and Abubaker, F. (2009).
Investigation into the controversial associa-
tion of streptococcus gallolyticus with colorectal
Frontiers in Cellular and Infection Microbiology www.frontiersin.org January 2014 | Volume 3 | Article 115 | 3
Markou and Apidianakis Pseudomonas aeruginosa in cancer
cancer and adenoma. BMC Cancer 9:403. doi:
10.1186/1471-2407-9-403
Adams, J. M., and Cory, S. (2007). The bcl-
2 apoptotic switch in cancer development
and therapy. Oncogene 26, 1324–1337. doi:
10.1038/sj.onc.1210220
Alexander, J. W., Boyce, S. T., Babcock, G. F.,
Gianotti, L., Peck, M. D., Dunn, D. L., et al.
(1990). The process of microbial translocation.
Ann. Surg. 212, 496–510. discussion: 511–512. doi:
10.1097/00000658-199010000-00012
Alverdy, J., Holbrook, C., Rocha, F., Seiden, L.,
Wu, R. L., Musch, M., et al. (2000). Gut-
derived sepsis occurs when the right pathogen
with the right virulence genes meets the right
host: evidence for in vivo virulence expression in
Pseudomonas aeruginosa. Ann. Surg. 232, 480–489.
doi: 10.1097/00000658-200010000-00003
Alverdy, J., Zaborina, O., and Wu, L. (2005). The
impact of stress and nutrition on bacterial-host
interactions at the intestinal epithelial surface.
Curr. Opin. Clin. Nutr. Metab. Care 8, 205–209.
doi: 10.1097/00075197-200503000-00016
An, G. (2008). Introduction of an agent-based multi-
scale modular architecture for dynamic knowledge
representation of acute inflammation. Theor. Biol.
Med. Model. 5, 11. doi: 10.1186/1742-4682-5-11
Andremont, A., Marang, B., Tancrede, C., Baume,
D., and Hill, C. (1989). Antibiotic treatment and
intestinal colonization by Pseudomonas aeruginosa
in cancer patients. Antimicrob. Agents Chemother.
33, 1400–1402. doi: 10.1128/AAC.33.8.1400
Apidianakis, Y., Pitsouli, C., Perrimon, N., and
Rahme, L. (2009). Synergy between bacterial
infection and genetic predisposition in intesti-
nal dysplasia. Proc. Natl. Acad. Sci. U.S.A. 106,
20883–20888. doi: 10.1073/pnas.0911797106
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M.,
Tomkovich, S., Uronis, J. M., Fan, T. J., et al.
(2012). Intestinal inflammation targets cancer-
inducing activity of the microbiota. Science 338,
120–123. doi: 10.1126/science.1224820
Babrowski, T., Romanowski, K., Fink, D., Kim, M.,
Gopalakrishnan, V., Zaborina, O., et al. (2013).
The intestinal environment of surgical injury
transforms Pseudomonas aeruginosa into a dis-
crete hypervirulent morphotype capable of caus-
ing lethal peritonitis. Surgery 153, 36–43. doi:
10.1016/j.surg.2012.06.022
Bangi, E., Pitsouli, C., Rahme, L. G., Cagan, R.,
and Apidianakis, Y. (2012). Immune response to
bacteria induces dissemination of ras-activated
drosophila hindgut cells. EMBO Rep. 13, 569–576.
doi: 10.1038/embor.2012.44
Berx, G., and van Roy, F. (2009). Involvement of
members of the cadherin superfamily in cancer.
Cold Spring Harb. Perspect. Biol. 1, a003129. doi:
10.1101/cshperspect.a003129
Bos, M. M., Smeets, L. S., Dumay, I., and de Jonge,
E. (2013). Bloodstream infections in patients with
or without cancer in a large community hospital.
Infection 41, 949–988. doi: 10.1007/s15010-013-
0468-1
Breitschwerdt, E. B., Linder, K. L., Day, M. J., Maggi,
R. G., Chomel, B. B., and Kempf, V. A. (2013).
Koch’s postulates and the pathogenesis of compar-
ative infectious disease causation associated with
bartonella species. J. Comp. Pathol. 148, 115–125.
doi: 10.1016/j.jcpa.2012.12.003
Cavallaro, U., and Christofori, G. (2004). Cell adhe-
sion and signalling by cadherins and ig-CAMs
in cancer. Nat. Rev. Cancer 4, 118–132. doi:
10.1038/nrc1276
Christofi, T., and Apidianakis, Y. (2013). Ras-
oncogenic drosophila hindgut but not midgut cells
use an inflammation-like program to dissemi-
nate to distant sites. Gut Microbes 4, 54–59. doi:
10.4161/gmic.22429
Collins, D., Hogan, A. M., and Winter, D. C. (2011).
Microbial and viral pathogens in colorectal cancer.
Lancet Oncol. 12, 504–512. doi: 10.1016/S1470-
2045(10)70186-8
Craven, D. E., Kunches, L. M., Lichtenberg, D. A.,
Kollisch, N. R., Barry, M. A., Heeren, T. C., et al.
(1988). Nosocomial infection and fatality in med-
ical and surgical intensive care unit patients. Arch.
Intern. Med. 148, 1161–1168. doi: 10.1001/arch-
inte.1988.00380050165024
de Lima, C. D. M., Calegari-Silva, T. C., Pereira, R.
M. S., de Oliveira Lima Santos, S. A., Lopes, U.
G., Plotkowski, M. C. M., et al. (2012). ExoU
activates NF-κB and increases IL-8/KC secre-
tion during Pseudomonas aeruginosa infection.
PLoS ONE 7:e41772. doi: 10.1371/journal.pone.
0041772
Driscoll, J. A., Brody, S. L., and Kollef, M. H.
(2007). The epidemiology, pathogenesis and treat-
ment of Pseudomonas aeruginosa infections. Drugs
67, 351–368. doi: 10.2165/00003495-200767030-
00003
Dunn, G. P., Ikeda, H., Bruce, A. T., Koebel, C.,
Uppaluri, R., Bui, J., et al. (2005). Interferon-
gamma and cancer immunoediting. Immunol. Res.
32, 231–245. doi: 10.1385/IR:32:1-3:231
Evan, G., and Littlewood, T. (1998). A matter of
life and cell death. Science 281, 1317–1322. doi:
10.1126/science.281.5381.1317
Gellatly, S. L., and Hancock, R. E. (2013).
Pseudomonas aeruginosa: new insights into
pathogenesis and host defenses. Pathog.
Dis. 67, 159–173. doi: 10.1111/2049-632X.
12033
Hardy, R. G., Meltzer, S. J., and Jankowski, J.
A. (2000). ABC of colorectal cancer. Molecular
basis for risk factors. BMJ 321, 886–889. doi:
10.1136/bmj.321.7265.886
Hentges, D. J., Stein, A. J., Casey, S. W., and Que, J.
U. (1985). Protective role of intestinal flora against
infection with Pseudomonas aeruginosa in mice:
influence of antibiotics on colonization resistance.
Infect. Immun. 47, 118–122.
Holt, P. G., Strickland, D. H., Wikstrom, M. E., and
Jahnsen, F. L. (2008). Regulation of immuno-
logical homeostasis in the respiratory tract.
Nat. Rev. Immunol. 8, 142–152. doi: 10.1038/
nri2236
Hussain, S. P., Hofseth, L. J., and Harris,
C. C. (2003). Radical causes of cancer.
Nat. Rev. Cancer 3, 276–285. doi: 10.1038/
nrc1046
Kerr, K. G., and Snelling, A. M. (2009). Pseudomonas
aeruginosa: a formidable and ever-present
adversary. J. Hosp. Infect. 73, 338–344. doi:
10.1016/j.jhin.2009.04.020
Levison, M. E. (1973). Effect of colon flora and short-
chain fatty acids on growth in vitro of Pseudomonas
aeruginosa and enterobacteriaceae. Infect. Immun.
8, 30–35.
Long, J., Zaborina, O., Holbrook, C., Zaborin, A.,
and Alverdy, J. (2008). Depletion of intesti-
nal phosphate after operative injury activates
the virulence of P. aeruginosa causing lethal
gut-derived sepsis. Surgery 144, 189–197. doi:
10.1016/j.surg.2008.03.045
Lowe, S. W., Cepero, E., and Evan, G. (2004). Intrinsic
tumour suppression. Nature 432, 307–315. doi:
10.1038/nature03098
Macdonald, I. A., and Kuehn, M. J. (2013).
Stress-induced outer membrane vesicle
production by Pseudomonas aeruginosa. J.
Bacteriol. 195, 2971–2981. doi: 10.1128/JB.
02267-12
Marshall, J. C., Christou, N. V., and Meakins, J. L.
(1993). The gastrointestinal tract. The “undrained
abscess” of multiple organ failure. Ann. Surg.
218, 111–119. doi: 10.1097/00000658-199308000-
00001
Montassier, E., Batard, E., Gastinne, T., Potel, G., and
de La Cochetiere, M. F. (2013). Recent changes in
bacteremia in patients with cancer: a systematic
review of epidemiology and antibiotic resistance.
Eur. J. Clin. Microbiol. Infect. Dis. 32, 841–850. doi:
10.1007/s10096-013-1819-7
Okuda, J., Hayashi, N., Okamoto, M., Sawada, S.,
Minagawa, S., Yano, Y., et al. (2010). Translocation
of Pseudomonas aeruginosa from the intesti-
nal tract is mediated by the binding of ExoS
to an na, K-ATPase regulator, FXYD3. Infect.
Immun. 78, 4511–4522. doi: 10.1128/IAI.
00428-10
Oliveira, A. L., de Souza, M., Carvalho-Dias, V. M.,
Ruiz, M. A., Silla, L., Tanaka, P. Y., et al. (2007).
Epidemiology of bacteremia and factors associ-
ated with multi-drug-resistant gram-negative bac-
teremia in hematopoietic stem cell transplant
recipients. Bone Marrow Transplant. 39, 775–781.
doi: 10.1038/sj.bmt.1705677
Osmon, S., Ward, S., Fraser, V. J., and Kollef,
M. H. (2004). Hospital mortality for patients
with bacteremia due to staphylococcus aureus or
Pseudomonas aeruginosa. Chest 125, 607–616. doi:
10.1378/chest.125.2.607
Papoff, P., Ceccarelli, G., d’Ettorre, G., Cerasaro, C.,
Caresta, E., Midulla, F., et al. (2012). Gut microbial
translocation in critically ill children and effects
of supplementation with pre- and pro biotics.
Int. J. Microbiol. 2012, 151393. doi: 10.1155/2012/
151393
Rafla, K., and Tredget, E. E. (2011). Infection con-
trol in the burn unit. Burns 37, 5–15. doi:
10.1016/j.burns.2009.06.198
Safdar, A., and Armstrong, D. (2001). Infectious
morbidity in critically ill patients with can-
cer. Crit. Care Clin. 17, 531–570, vii–viii. doi:
10.1016/S0749-0704(05)70198-6
Sax, H., Uckay, I., Balmelli, C., Bernasconi, E.,
Boubaker, K., Muhlemann, K., et al. (2011).
Overall burden of healthcare-associated infec-
tions among surgical patients. Results of a
national study. Ann. Surg. 253, 365–370. doi:
10.1097/SLA.0b013e318202fda9
Schwitalla, S., Fingerle, A. A., Cammareri, P.,
Nebelsiek, T., Göktuna, S. I., Ziegler, P. K.,
et al. (2013). Intestinal tumorigenesis initi-
ated by dedifferentiation and acquisition of
stem-cell-like properties. Cell 152, 25–38. doi:
10.1016/j.cell.2012.12.012
Frontiers in Cellular and Infection Microbiology www.frontiersin.org January 2014 | Volume 3 | Article 115 | 4
Markou and Apidianakis Pseudomonas aeruginosa in cancer
Seal, J. B., Alverdy, J. C., Zaborina, O., and An, G.
(2011). Agent-based dynamic knowledge represen-
tation of Pseudomonas aeruginosa virulence acti-
vation in the stressed gut: towards characterizing
host-pathogen interactions in gut-derived sepsis.
Theor. Biol. Med. Model. 8, 33. doi: 10.1186/1742-
4682-8-33
Selgrad, M., Malfertheiner, P., Fini, L., Goel, A.,
Boland, C. R., and Ricciardiello, L. (2008). The
role of viral and bacterial pathogens in gastroin-
testinal cancer. J. Cell. Physiol. 216, 378–388. doi:
10.1002/jcp.21427
Stoodley, B. J., and Thom, B. T. (1970). Observations
on the intestinal carriage of Pseudomonas
aeruginosa. J. Med. Microbiol. 3, 367–375. doi:
10.1099/00222615-3-3-367
Stuart, B., Lin, J. H., and Mogayzel, P. J. Jr. (2010).
Early eradication of Pseudomonas aeruginosa in
patients with cystic fibrosis. Paediatr. Respir. Rev.
11, 177–184. doi: 10.1016/j.prrv.2010.05.003
Sundin, C., Thelaus, J., Broms, J. E., and Forsberg,
A. (2004). Polarisation of type III translocation
by Pseudomonas aeruginosa requires PcrG, PcrV
and PopN. Microb. Pathog. 37, 313–322. doi:
10.1016/j.micpath.2004.10.005
Tabrah, F. L. (2011). Koch’s postulates, carnivorous
cows, and tuberculosis today. Hawaii Med. J. 70,
144–148.
Tafe, L. J., and Ruoff, K. L. (2007). Streptococcus bovis:
answers and questions. Clin. Microbiol. Newsl. 29,
49–55. doi: 10.1016/j.clinmicnews.2007.03.004
Thuong, M., Arvaniti, K., Ruimy, R., de la Salmoniere,
P., Scanvic-Hameg, A., Lucet, J. C., et al. (2003).
Epidemiology of Pseudomonas aeruginosa and
risk factors for carriage acquisition in an inten-
sive care unit. J. Hosp. Infect. 53, 274–282. doi:
10.1053/jhin.2002.1370
Tjalsma, H., Boleij, A., Marchesi, J. R., and Dutilh, B.
E. (2012). A bacterial driver – passenger model for
colorectal cancer: beyond the usual suspects. Nat.
Rev. Microbiol. 10, 575–582. doi: 10.1038/nrmi-
cro2819
Toprak, N. U., Yagci, A., Gulluoglu, B. M., Akin, M.
L., Demirkalem, P., Celenk, T., et al. (2006). A
possible role of bacteroides fragilis enterotoxin in
the aetiology of colorectal cancer. Clin. Microbiol.
Infect. 12, 782–786. doi: 10.1111/j.1469-0691.2006.
01494.x
Vaupel, P., and Mayer, A. (2007). Hypoxia in can-
cer: significance and impact on clinical out-
come. Cancer Metastasis Rev. 26, 225–239. doi:
10.1007/s10555-007-9055-1
Vikström, E., Bui, L., Konradsson, P., andMagnusson,
K. E. (2009). The junctional integrity of
epithelial cells is modulated by Pseudomonas
aeruginosa quorum sensing molecule through
phosphorylation-dependent mechanisms. Exp.
Cell Res. 315, 313–326. doi: 10.1016/j.yexcr.2008.
10.044
Vuotto, F., Berthon, C., Lemaitre, N., Duhamel,
A., Balkaran, S., Le Ray, E., et al. (2013).
Risk factors, clinical features, and outcome of
Pseudomonas aeruginosa bacteremia in patients
with hematologic malignancies: a case-control
study. Am. J. Infect. Control 41, 527–530. doi:
10.1016/j.ajic.2012.07.012
Worth, L. J., and Slavin, M. A. (2009).
Bloodstream infections in haematology: risks
and new challenges for prevention. Blood
Rev. 23, 113–122. doi: 10.1016/j.blre.2008.
10.003
Zaborina, O., Kohler, J. E., Wang, Y., Bethel, C.,
Shevchenko, O.,Wu, L., et al. (2006). Identification
of multi-drug resistant Pseudomonas aeruginosa
clinical isolates that are highly disruptive to
the intestinal epithelial barrier. Ann. Clin.
Microbiol. Antimicrob. 5, 14. doi: 10.1186/1476-
0711-5-14
Received: 26 September 2013; accepted: 22 December
2013; published online: 07 January 2014.
Citation: Markou P and Apidianakis Y
(2014) Pathogenesis of intestinal Pseudomonas
aeruginosa infection in patients with
cancer. Front. Cell. Infect. Microbiol. 3:115. doi:
10.3389/fcimb.2013.00115
This article was submitted to the journal Frontiers in
Cellular and Infection Microbiology.
Copyright © 2014 Markou and Apidianakis. This is
an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licen-
sor are credited and that the original publication
in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduc-
tion is permitted which does not comply with these
terms.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org January 2014 | Volume 3 | Article 115 | 5
